19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

19th CUA Genitourinary Oncology Conference | Professor Kan Gong: Taking a Pragmatic View of AI in Clinical Practice While Building a China-Specific Evidence Base for Urologic Oncology

The 19th Chinese Urological Association (CUA) Genitourinary Oncology Conference was successfully held in Beijing on July 3–4, 2026. Centered on the theme "Advancing Frontiers, Standardizing Care, and Driving Collaborative Innovation," the meeting featured in-depth discussions on precision oncology, early screening and prevention of prostate cancer, and the development of a robust domestic clinical research ecosystem, highlighting both the latest advances and the key challenges facing urologic oncology in China.
Blood Advances Study | Director Zhihui Li’s Team Demonstrates Survival Benefit of HSCT in Advanced ENKTCL, Paving the Way for Precision Risk Stratification

Blood Advances Study | Director Zhihui Li’s Team Demonstrates Survival Benefit of HSCT in Advanced ENKTCL, Paving the Way for Precision Risk Stratification

Extranodal NK/T-cell lymphoma (ENKTCL) is a rare, highly aggressive lymphoid malignancy closely associated with Epstein–Barr virus (EBV) infection. Patients with advanced-stage or relapsed/refractory (R/R) disease continue to face poor outcomes, making effective treatment a longstanding clinical challenge. Recently, Director Zhihui Li and colleagues from Beijing GoBroad Boren Hospital published a study in Blood Advances entitled "HSCT May Improve Survival in Advanced Extranodal NK/T-Cell Lymphoma: A Single-Center Retrospective Study."
BCJ Publishes Chinese CMML Cohort Study | Simpler Variables, More Accurate Risk Stratification? Investigators Discuss Why the BLAST Model Outperformed CPSS

BCJ Publishes Chinese CMML Cohort Study | Simpler Variables, More Accurate Risk Stratification? Investigators Discuss Why the BLAST Model Outperformed CPSS

Chronic myelomonocytic leukemia (CMML) is a highly heterogeneous myeloid malignancy in which early identification of high-risk patients is critical for timely referral to allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recently, a collaborative team led by Professor Zheng Ge of Zhongda Hospital, Southeast University, and Professor Shuqian Xu of Qilu Hospital, Shandong University, published a study in Blood Cancer Journal entitled "BLAST demonstrates higher prognostic accuracy for survival than CPSS in Chinese patients with chronic myelomonocytic leukemia."
CSCO 10th Hematologic Malignancies Congress | Director Yajing Zhang: Moving Beyond “Target-Centric” Thinking to Redefine Lifelong Management of Hematologic Malignancies Through a Systems-Based Approach

CSCO 10th Hematologic Malignancies Congress | Director Yajing Zhang: Moving Beyond “Target-Centric” Thinking to Redefine Lifelong Management of Hematologic Malignancies Through a Systems-Based Approach

From July 10–12, 2026, the 10th Hematologic Malignancies Congress of the Chinese Society of Clinical Oncology (CSCO) was held in Harbin, China. Over the past decade, the meeting has grown into one of China's premier academic forums for hematologic oncology. This year's congress not only celebrated ten years of scientific achievement but also marked an important milestone for future innovation.
BOC 2026 | Spotlight on Homegrown Innovation: Professor Zhitao Ying Interprets the Lymphoma Highlights from the Annual Progress in Clinical Oncology in China 2025

BOC 2026 | Spotlight on Homegrown Innovation: Professor Zhitao Ying Interprets the Lymphoma Highlights from the Annual Progress in Clinical Oncology in China 2025

From July 3–4, 2026, the 2026 Best of Clinical Oncology (BOC) Academic Conference & Best of CSCO 2026 China was held in Hohhot, Inner Mongolia. This year's meeting marked the transformation of the former "BOA/BOC" conference into BOC, reflecting a significant shift in academic focus—from primarily introducing and interpreting international advances to highlighting China's own original oncology research.
EHA Conversations | Director Zhihui Li & Professor Yi Lin: Advancing CAR-T Manufacturing Through Innovation and Process Optimization

EHA Conversations | Director Zhihui Li & Professor Yi Lin: Advancing CAR-T Manufacturing Through Innovation and Process Optimization

Bridging expertise across continents to explore the future of cellular therapy, Oncology Frontier – Hematology Frontier hosted an in-depth conversation during the 2026 European Hematology Association (EHA) Congress featuring Director Zhihui Li of Beijing GoBroad Boren Hospital and Professor Yi Lin of the Mayo Clinic. Centered on the theme "CAR-T Manufacturing: Scientific Advances and Technological Innovation," the discussion examined key developments shaping the next generation of CAR-T therapy, including rapid manufacturing platforms, in vivo CAR-T technologies, novel CAR molecular designs, and the emerging issue of secondary malignancies. Together, the two experts outlined a compelling vision for improving CAR-T manufacturing, enhancing safety, and accelerating clinical translation.
CUDA 2026 | Professor Xuepei Zhang: Advancing High-Quality Urologic Care and Regional Collaboration from Zhengzhou

CUDA 2026 | Professor Xuepei Zhang: Advancing High-Quality Urologic Care and Regional Collaboration from Zhengzhou

From June 11–14, 2026, the 2026 Annual Meeting of the Chinese Urological Association of the Chinese Medical Doctor Association (CUDA) was held in Zhengzhou, Henan Province. The meeting was hosted by the Chinese Medical Doctor Association (CMDA) and the Chinese Urological Association of the CMDA (CUDA), and jointly organized by The First Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, and The First Affiliated Hospital of Henan University, with additional support from Henan Cancer Hospital, The First Affiliated Hospital of Henan University of Chinese Medicine, and The Second Affiliated Hospital of Zhengzhou University.
CUDA 2026 | Professor Lianqu Wang: Leveraging a Century of Medical Education and Regional Healthcare Strengths to Advance Integrated Clinical Care, Education, and Research in Urology at Henan University

CUDA 2026 | Professor Lianqu Wang: Leveraging a Century of Medical Education and Regional Healthcare Strengths to Advance Integrated Clinical Care, Education, and Research in Urology at Henan University

Hosted by the Chinese Medical Doctor Association (CMDA) and the Chinese Urological Association of the CMDA (CUDA), the 2026 CUDA Annual Meeting was held in Zhengzhou, Henan Province, from June 11–14, 2026. The meeting was jointly organized by The First Affiliated Hospital of Zhengzhou University, Henan Provincial People's Hospital, and The First Affiliated Hospital of Henan University, with additional support from Henan Cancer Hospital, The First Affiliated Hospital of Henan University of Chinese Medicine, and The Second Affiliated Hospital of Zhengzhou University.
CUDA 2026 | Professor Linhui Wang: Advancing Precision Kidney-Sparing Surgery in the Modern Era of Renal Cancer Care

CUDA 2026 | Professor Linhui Wang: Advancing Precision Kidney-Sparing Surgery in the Modern Era of Renal Cancer Care

Hosted by the Chinese Medical Doctor Association (CMDA) and the Chinese Urological Association of the CMDA (CUDA), the 2026 CUDA Annual Meeting was held in Zhengzhou, Henan Province, from June 11–14, 2026. Continuing the discipline's mission of "Healthy China, Urology at the Forefront," this year's conference was themed "Collaboration and Innovation for Future Development." The scientific program featured in-depth discussions on precision surgery, advances in minimally invasive techniques, and the evolving role of robotic surgery through expert lectures, live surgical demonstrations, and multidisciplinary forums.
Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

Professor Benlong Yang: Breast Surgery Enters the Era of De-escalation and Individualized Care in Precision Oncology | 2026 CACA Cancer Prevention and Screening Conference

The 2026 CACA Cancer Prevention and Screening Conference recently opened in Hangzhou, bringing together leading oncologists, researchers, and industry experts from across China to discuss advances in cancer prevention, early detection, multidisciplinary collaboration, and translational research. Hosted by the Chinese Anti-Cancer Association (CACA) and its Cancer Prevention and Screening Committee, the meeting aligns with the goals of the Healthy China 2030 initiative by promoting earlier intervention throughout the cancer care continuum.